Also known as: Chia Tai Tianqing Pharmaceutical group, Chia Tai Tianqing Pharmaceutical Group
Chia Tai Tianqing Pharmaceutical Group is a Chinese pharmaceutical company with integrated R&D, manufacturing, marketing, sales, and distribution capabilities. The company has major strengths in liver disease and oncology-related therapeutic areas.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.
